We have constructed a polyomavirus mutant genome which exhibits an increased immortalization potential when transfected into primary rat embryo fibroblasts. The mutation is a 30-base-pair deletion (nucleotides 1367 through 13%) that inactivates the transforming potential of middle T but activates some of the properties of large T associated with neoplastic transformation. Unlike the wild-type large T, the mutant large T can fully complement polyoma middle T in the tumorigenic process in vivo as well as in the transformation of primary cells in vitro. The activity of the mutant can be explained by its inability to replicate in cells and, hence, its inability to exert a cytopathic effect after gene transfer at high multiplicity. A recombinant which encodes the middle and small T antigens, but not the large T antigen, can also elicit a fully transformed phenotype when introduced into primary rat fibroblasts. These results confirm previous observations from this laboratory indicating that two, and not three, viral gene functions are required for polyomavirus-mediated oncogenic transformation.
The early region of the polyomavirus genome encodes three distinct proteins, the large T (plt), middle T (ppmt), and small T (pst) antigens (see reference 31 for a review). Of these three proteins, the pmt antigen plays a central role in both oncogenic transformation in vitro (32) and tumorigenesis in vivo (3, 5) . pmt alone is capable of transforming established cells in culture (32) , but, unlike the wild-type viral genome, it cannot efficiently transform primary cells (24) nor induce tumors when inoculated into newborn rats (2) . Thus, functions other than those expressed by the pmt antigen may be required for the elaboration of all the properties associated with neoplastic transformation. The role exerted by the other two viral proteins is still a matter of controversy. Since the ras oncogene can transform primary rodent cells after cotransfer with polyoma plt, adenovirus ElA, or the myc oncogene (14, 26) , one would expect simultaneous transfer of both the pmt and plt genes to result in the establishment of the fully transformed phenotype in vitro as well as in vivo. In agreement with this scheme, Rassoulzadegan et al. (25) have observed that cell lines established by transfer of plt into primary fibroblasts can be subsequently transformed by transfer of the pmt gene. However, when both genes were simultaneously transferred into cells, no stable transformant could be isolated by focus formation. Combinations of pmt and pst or plt and pst were similarly inefficient. Cuzin et al. (8) have reported that transformation of the fully normal rat embryo fibroblasts can only be achieved by the wild-type genome or by a combination of modified genomes that allow simultaneous synthesis of the three early proteins.
By contrast, studies from this laboratory have shown that the pst protein can complement pmt in the absence of plt for tumor induction in animals (2) . Similar complementary functions can also be exerted by the simian virus 40 (SV40) large T antigen as well as by one or several products of the adenovirus ElA region (3) . Thus, as for the in vitro transformation of primary cells, the in vivo steps in poly-omavirus-mediated tumorigenesis depend on additional cellular alterations beyond the acquisition of the polyomavirus transforming gene. As reported by this laboratory, such alterations can be achieved by either polyoma pst antigen or other early gene products from related DNA tumor viruses. Some of these genes, such as SV40 large T (1, 6, 7, 23) and ElA (11) , appear to be associated with functions that confer on primary cells the ability to grow indefinitely in culture. However, although the polyoma plt gene is capable of immortalizing primary cells (25) , the combination of the plt and pmt genes fails to induce tumors in newborn rats (3) . It seems, therefore, that certain experimental conditions do not allow simultaneous expression of both genes in vivo or that plt is not sufficient to complement pmt in the tumorigenic process.
In this work, we have attempted to mutagenize the polyoma large T gene in such a way as to enable it to complement pmt in tumorigenesis. We describe the construction of a plt deletion mutant which exhibits an increased immortalization potential, and we show that the mutation enables plt to fully complement pmt not only in the tumorigenic process in vivo but also in the transformation of primary rat fibroblasts in vitro. These results demonstrate that two, and not three, viral gene functions are required for polyomavirus-mediated malignant transformation.
MATERIALS AND METHODS
Plasmids. pPyLT1 (Fig. 1) carries the polyomavirus large T gene. This plasmid was constructed by deleting the large T protein intron from the polyomavirus genome (35) . pMT3 is a recombinant encoding only the middle T antigen (2) . It was obtained by deleting two HindIII fragments from pPyMT1 (32) . bclO51 is a modified polyoma genome expressing only the middle and small T antigens (21) . pPB21 carries the polyomavirus genome (A2 strain) in the BamHI site of pBR322 (9) . pSV2-neo is a plasmid expressing neo, a dominant selective marker (28) . pneo-LT1 (Fig. 1) was constructed by inserting the polyoma large T gene into the BamHI site of pSV2-neo. pMLT1 (Fig. 1) DNA replication assay. CsCl gradient-purified, supercoiled plasmid DNAs were transfected into mouse 3T6 cells by a modification of the DEAE-dextran transfection technique (17, 30) . At 72 h posttransfection, low-molecular-weight plasmid DNA was isolated by the Hirt extraction procedure (10) . Portions of the DNA samples were sequentially digested with BclI and DpnI restriction endonucleases, and subjected to electrophoresis through 1.0% (wt/vol) agarose gels. The DNA fragments were transferred to nitrocellulose filters (27) and hybridized to a [32P]-labeled RNA probe as previously described (8a).
RESULTS
Isolation of plt mutants. We wished to determine whether the failure of pPyLT1 to complement pmt in tumorigenesis was due to a lack of activity of the plt antigen or to a cytopathic effect exerted by the protein, as had previously been observed in transformation of primary embryo fibroblasts (14, 18) . We postulated that to complement pmt in an in vivo assay, plt should lose its toxicity while retaining most of its immortalizing activity. Initial experiments were carried out with a cloned fragment of the pit gene, termed pLT3, that allowed synthesis of the N-proximal half of the plt antigen implicated in alteration of serum dependency and immortalization (25) . Although a similar construction had been shown to complement EJ ras in the transformation of primary cells (14) , injection of both pLT3 and pMT3 (truncated plt plus pmt) failed to induce tumors in newborn rats (Table 1) . We then attempted to determine whether pLT3 had retained all of the immortalizing potential of pPyLT1, the intactplt gene. To this end, we used a simple immortalization assay to detect the ability of recombinant plasmids to modify the growth of rat embryo fibroblasts. The plasmids were linked to pSV2-neo ( Fig. 1 ) and introduced into primary cells by the calcium phosphate transfection procedure (33) . Transfection with pneo-LT1 and pneo-LT3 gave rise to continuous cell lines with frequencies of 33.1 and 21.3%, respectively (Table  2) . Thus, although the truncated plt antigen was able to immortalize primary cells, it did so with a frequency significantly lower (P -0.056) than that observed with the intact protein. For pMLT97. About 5% of the G418-resistant colonies had an altered morphology. Supercoiled plasmid DNA (6 p.g) was cotransfected with 2 ,ug of pSV2-neo. Magnification, x 100. presence of pSV2-neo yielded several G418-resistant colonies (three of four colonies) that exhibited the same partially transformed phenotype (data not shown). Second, introduction of pMLT97 into primary rat embryo fibroblasts without a selection marker produced foci of oncogenically transformed cells (Table 2) , some of which grew rapidly as did tumors upon transplantation into nude mice (Table 3) or Fischer rats (data not shown). Transfection of pMLT1 with pSV2-neo also led to the formation of dense colonies (Fig.  2) . However, in this case, the total number of colonies was greatly reduced (1 versus 86), presumably because of a toxic effect of the large T antigen. This toxicity of large T has been observed in several instances (14, 18) and could very well explain why simultaneous transfer of both pmt and plt genes failed to induce tumors in vivo (Table 1) as well as transformation of primary cells in vitro (25) ( Table 2) .
Cuzin et al. (8) reported that bc1051, a recombinant encoding only the middle and small T proteins (21), did not transform rat embryo fibroblasts. This result seemed paradoxical because experiments from this laboratory had shown that the same recombinant induced tumors in newborn rats with virtually the efficiency of wild-type genomic DNA (2). We found, in agreement with Cuzin et al. (8) , that no stably transformed line could be isolated by focus formation after transfer of bc1051 into primary rat embryo fibroblasts (Table  2 ). However, under the conditions of transfection with the neo marker, bc1051 produced dense colonies of transformed cells (Fig. 2) . Most of the cell lines derived from these colonies exhibited a partially transformed phenotype. The cells appeared large and flat and resembled immortalized cells. By contrast, some cell lines displayed an irregular growth pattern in culture and had a morphology characteristic of fully transformed cells. Unlike the flat cells, these cells grew in soft agar and were tumorigenic when inoculated into nude mice or Fischer rats (Table 3) .
Replication of plasmid DNAs. It was shown by Land et al. (14) that the plt gene strongly inhibited establishment of cotransfected genes, which might be due to the presence of the polyoma replication origin together with the gene for the entire large T antigen. This might allow the large T antigen to trigger repeated rounds of viral DNA replication and, in turn, create a cytopathic effect. We wished to see whether the capability of pLT97 to complement pmt in both transformation and tumorigenesis could be explained by the inability of the mutant protein to trigger viral DNA replication. To this end, we transfected permissive mouse 3T6 cells by a modification of the DEAE-dextran procedure (17, 30) and assessed the capacity of both pPyLT1 and its deletion mutant pLT97 to replicate in these cells. The low-molecularweight DNA Fig. 3 . Unlike the control plasmid pPyLT1, the deletion mutant pLT97 was not able to replicate in permissive cells.
Transfer of the mutation into the pmt gene. The precise location of the deletion in pLT97 was determined by DNA sequencing. We found that the plt gene had an in-frame deletion of 30 bp between nucleotides 1366 and 1397 (Fig.  4a) . This deletion removed 10 amino acids from the plt (32) . The resulting plasmid, pMT97 (Fig. 5) , contained the pmt antigen-coding sequence with a 30-bp deletion affecting the protein as illustrated in Fig. 4b . Although pMT3, the wild-type pmt gene, is able to transform FR3T3 cells in culture (2), its deletion mutant pMT97 was inactive (data not shown). By exchanging appropriate restriction fragments (Fig. 5) , we also transferred the mutation into pPB21, a plasmid carrying the entire polyoma genome (9) and capable of expressing the three polyoma early proteins. The deletion in pPB21 affected both the middle and large T antigens (Fig. 4b) but not the small T antigen. Mutant pPB97 can therefore be considered as a mit mutant, i.e., a mutant affected in both pmt and plt gene functions. Although pPB21 was highly tumorigenic in newborn rats, inoculation of its deletion mutant pPB97 failed to induce tumors (Table  1) . Taken together, these results indicate that the 30-bp deletion severely impaired or inactivated the transforming and tumorigenic potential of the pmt gene.
DISCUSSION
We have shown that only two of the three viral gene functions are required for the polyomavirus-mediated transformation of primary cells. One is conferred by the pmt antigen, the transforming protein, whereas the second one can be conferred by either small T or large T. This is in agreement with previous studies from this laboratory showing that pmt requires the presence of either polyoma small T or an immortalizing gene from a related DNA tumor virus to induce tumors in newborn rats (3) . These results can be interpreted by a multistep process of carcinogenesis: a first step in which cells are prevented from senescing (immortalization), and a second one involving the acquisition of phenotypes characteristic of malignant cells (completion). Thus, some viral and cellular transforming genes can be classified operationally into two complementation groups, each group defining a different step required for transformation of primary cells in vitro (14, 22, 26) , as well as induction of tumors in vivo (3). Although polyoma small T is operationally very similar to the immortalizing genes, it cannot be implicated in establishment and immortalization functions (25) . This suggests that all the genes that complement the transforming functions of pmt do not create identical changes in cellular behavior but may, on the contrary, interact with different cellular targets. Polyomavirus has, in fact, developed three distinct oncogenes, and it has been reported that a function of the small T protein is necessary in addition to and in conjunction with the functions of the large and middle T proteins for transformation of primary cells (8) .
The results presented here show that this is not the case.
Transfection of the polyoma genomes with the neo marker yielded cell lines that displayed only a partially transformed phenotype. For several reasons, we believe that this is due to the neo selection rather than to the lack of oncogenic potential of the combination of genes transfected. Autoradiogram of pLT97 subjected to chemical degradation and electrophoresis. pLT97 was digested by AccI, and the fragment spanning the sequences between nucleotides 368 and 1500 was isolated by agarose gel electrophoresis. After labeling with [cx-32P]ddATP and terminal transferase, the DNA was cleaved by AvaI, and the AvaI-AccI fragment (nucleotides 1016 through 1500) was isolated by polyacrylamide gel electrophoresis and sequenced by the method of Maxam and Gilbert (16) . The products were separated on 8% polyacrylamide gels. (b) Sequence of the region of polyoma DNA (5' strand) including the deletion found in pLT97 and predicted modifications in the sequence of large T antigen. After transfer of the deletion in pMT3 (Fig. 5) , the structure of middle T antigen is affected as indicated. In pPB97, a genome encoding the three early proteins (Fig. 5) , the deletion affects the structure of both middle and large T antigens. (14, 26) , has been shown to behave as a second-step conversion gene in immortalized Chinese hamster cells (29) . These results show that some oncogenes can have both step 1 (immortalization) and step 2 (conversion) transforming potential, depending on the assay system chosen. They also suggest that classification of oncogenes into different complementation groups on the basis of their transformation properties may be more artificial than real.
As to the role of large T, our work shows that this oncogene is sufficient to complement pmt in transformation, even when both genes are transferred simultaneously into cells. However, the full-sized plt appears to be very inefficient in the process. Land et al. (14) could not study the activity of the intact protein because of a toxic effect after gene transfer at high multiplicity by the calcium phosphate transfection method. This toxicity was not observed when we studied the effect of large T in immortalization, but it was apparent when pMLT1 (pmt plus plt) was cotransfected with pSV2-neo in transformation assays. It is interesting to note that tumors induced by inoculating polyomavirus or its DNA into animals invariably contain deletions or rearrangements in the distal portion of the polyoma early region (5, 12 consequently free viral genomes (15) . One would expect the tumors to produce, in addition to the middle T antigen, a modified large T antigen equivalent to mutant pLT97 or, more likely, the small T antigen. The latter, which is sufficient to complement middle T in tumorigenesis, is indeed found in tumors induced by polyomavirus DNA (2, 5) . Truncated forms of large T antigen have been found in transformed cells (13) but not in tumors (12) , and it is not clear whether they have any role to play in transformation (34) . The large T fragments arise very likely as a consequence of deletions and rearrangements affecting the distal half of the early gene region which precludes the synthesis of large T antigen (5, 12) but not that of the middle and small T antigens. The deletion in pLT97 may have occurred in a very particular region of the large T gene; i.e., removal of a few amino acids from some parts of the protein may result in an activation of its biological properties. Although the activity of the mutant is likely due to its inability to replicate and, hence, its inability to exert a toxic effect, its efficiency in both immortalization and complementation of pmt is reminiscent of proto-oncogene activation. However, because the deletion occurs in the region coding for the C terminus of middle T antigen, it inactivates the transforming and tumorigenic functions of the genome. For this reason, mutations analogous to pPB97 are unlikely to be generated in vivo.
